ArticleScientific reports2024
Development and psychometric validation of a novel scale for measuring 'psychedelic preparedness'.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07737990 (Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Methodological fragmentation and integration priorities in psychedelic-assisted therapy assessment: a scoping review.Frontiers in psychiatry · 2026Pooled it
- The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research.Journal of psychopharmacology (Oxford, England) · 2026Trial
- Medical and Psychiatric Consultation for Patients Considering State-Regulated Psilocybin Services: A Risk-Reduction Model and Two Illustrative Cases.Research square · 2026Article
- Speech markers of psychological change following a psychedelic 5-MeO-DMT retreat.Journal of psychopharmacology (Oxford, England) · 2026Article
- Not a Standalone Treatment: Considerations for Psychedelic-Assisted Therapy.Brain and behavior · 2026Review
- Article
- Article
- Traumatic Psychedelic Experiences.Current topics in behavioral neurosciences · 2026Review
- Level of preparedness to use psilocybin among individuals seeking psychedelic risk reduction: a retrospective study of a pilot psychiatric consultation service.Frontiers in public health · 2026Article
- Deconstructing Psychedelic Phenomenology: A Thematic Analysis of Discrete Phases of the Psychedelic Experience.Brain and behavior · 2025Article
- Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies.Frontiers in psychology · 2025Article
- Protective Behavioral Strategies for Psychedelic Use: A Mini Review of the Evidence.Psychedelic medicine (New Rochelle, N.Y.) · 2024Article
- Strategies for resolving challenging psychedelic experiences: insights from a mixed-methods study.Scientific reports · 2024Article
- Validation of the imperial psychedelic predictor scale.Psychological medicine · 2024Article
- Development of a digital intervention for psychedelic preparation (DIPP).Scientific reports · 2024Article
- Development of the Protective Strategies for Psychedelics Scale: A novel inventory to assess safety strategies in the context of psychedelics.Journal of psychopharmacology (Oxford, England) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Preparing participants for psychedelic experiences is crucial for ensuring these experiences are safe and, potentially beneficial. However, there is currently no validated measure to assess the extent to which participants are well-prepared for such experiences. Our study aimed to address this gap by developing, validating, and testing the Psychedelic Preparedness Scale (PPS). Using a novel iterative Delphi-focus group methodology ('DelFo'), followed by qualitative pre-test interviews, we incorporated the perspectives of expert clinicians/researchers and of psychedelic users to generate items for the scale. Psychometric validation of the PPS was carried out in two large online samples of psychedelic users (N = 516; N = 716), and the scale was also administered to a group of participants before and after a 5-7-day psilocybin retreat (N = 46). Exploratory and confirmatory factor analysis identified four factors from the 20-item PPS: Knowledge-Expectations, Intention-Preparation, Psychophysical-Readiness, and Support-Planning. The PPS demonstrated excellent reliability (ω = 0.954) and evidence supporting convergent, divergent and discriminant validity was also obtained. Significant differences between those scoring high and low (on psychedelic preparedness) before the psychedelic experience were found on measures of mental health/wellbeing outcomes assessed after the experience, suggesting that the scale has predictive utility. By prospectively measuring modifiable pre-treatment preparatory behaviours and attitudes using the PPS, it may be possible to determine whether a participant has generated the appropriate mental 'set' and is therefore likely to benefit from a psychedelic experience, or at least, less likely to be harmed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.